Delix Therapeutics

Mark your calendar for the 63rd Annual Meeting of the American College of Neuropsychopharmacology, taking place December 8–11 in Phoenix, Arizona! Join us as our Senior Director of Pharmacology, Stephanie M., Ph.D. presents the groundbreaking potential of our lead #neuroplastogen, DLX-001, for treating a range?of #neuropsychiatric disorders. Our Chief Scientific Officer, Kurt Rasmussen, Ph.D., will discuss advancements in our other non-hallucinogenic therapies, including DLX-159, while our Chief Medical Officer, Aaron Koenig MD, will showcase compelling?Phase 1 results for DLX-001, highlighting its potential in treating Major Depressive Disorder. Don’t miss this opportunity to connect with our team and learn about the future of #brainhealth innovation. Register today: https://lnkd.in/dyWhDU5F

#Psychedelics hold immense promise for treating #neuropsychiatric disorders, but can scientists separate their therapeutic benefits from hallucinatory effects? In a groundbreaking study published in Science Magazine, Delix Therapeutics’s Co-Founder and Chief Innovation Officer, Professor David E. Olson, and the researchers at the University of California, Davis and UC Davis Institute for Psychedelics and Neurotherapeutics, leverage innovative neuronal reactivation techniques to uncover distinct neural circuits responsible for the therapeutic, anxiolytic effects versus the hallucinatory effects. This research strongly supports Delix’s underlying thesis and validates the feasibility of developing non-hallucinogenic #neuroplastogens that deliver the therapeutic benefits of psychedelics—safely, effectively, and at scale. Learn more about this exciting breakthrough:?https://lnkd.in/eU9cB7U9

Members and families of #TeamDelix spent a Sunday afternoon enjoying a beautiful fall day together, picking apples, soaking in the fresh air, and sharing lots of laughs. We also took a break from the office to enjoy a spirited game of darts, complete with friendly competition and some impressive bullseyes. At Delix Therapeutics, we value hard work, collaboration, and connection both in and outside the office. These moments outside of work bring our team even closer together, strengthening our commitment to the important work we do to advance #brainhealth.

Meet Retsina Meyer, PhD, Head of Corporate Strategy at Delix Therapeutics!? Whether it is working to help drive our strategic imperatives, navigating business development efforts, or engaging with potential partners, Retsina works closely with #TeamDelix to tackle complex challenges and foster growth in #brainhealth. Her leadership supports the teams across Delix in advancing #CNS treatments and developing novel #neuroplasticity therapies that are shaping the future of patient care.? We’re grateful for Retsina’s expertise and commitment to the Delix team and patients in support of transforming?lives through cutting-edge solutions and groundbreaking treatments for those who need them most.?

Join Delix Therapeutics CEO, Mark Rus, at the Longwood Healthcare Leaders CEO event in Boston, MA on October 28–29, where he?and fellow CEO panelists?will speak on?‘Identifying Next Generation Therapeutics’. Hear about Delix's?innovative pipeline of rapid-acting #neuroplastogens for a broad range of significant unmet needs in neuropsychiatry, neurology, and beyond.? For this panel and more, register here:?https://lnkd.in/dJ_8trZM.?? Cc?Rosana Kapeller?from ROME Therapeutics, Oliver Rosen?from Akamis Bio, Paul Peter Tak, MD PhD FMedSci?from Candel Therapeutics, and Brian Taylor?from SmartLabs #longwoodhealthcareleaders #NextGenTherapeutics

?? A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. ?? With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

Tomorrow, we stand with the global community in observing World?Alzheimer's Day, a day dedicated to raising awareness and challenging the stigma surrounding #Alzheimer’s disease. With nearly 55 million people affected worldwide, it's more important than ever to support ongoing research and foster a deeper understanding of this?disease?as we strive for better treatments for patients and their families. At Delix, we’re harnessing the brain’s innate ability to repair and restore neurons to treat a broad range of neurological illnesses. Our innovative #neuroplastogens?have the potential to revolutionize the treatment of a range of #CNS conditions, including Alzheimer's. Discover more about our innovative approach here:?https://lnkd.in/dqnHGFyw

Join our CEO, Mark Rus, at TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26. This exciting event will feature fireside chats and expert-led panel discussions exploring the latest breakthroughs in #neuropsychiatry. Don’t miss this opportunity to hear from industry leaders driving the future of neuropsychiatry!

We’re thrilled to be named a finalist for "Clinical Advancement of the Year” at the #BiotechWeekBoston BWB Awards! This recognition highlights the groundbreaking potential of emerging therapies that have successfully progressed through clinical trials and are poised to revolutionize healthcare in the near future. We are being recognized for our Proof of NonHallucinatory Platform trial where we demonstrated that our lead candidate, DLX-001, is non-hallucinogenic, non-psychotomimetic, and non-sedative, even at supratherapeutic doses. #TeamDelix is excited for an inspiring evening, celebrating the incredible achievements of all the nominees who are driving #innovation and making a lasting impact on patients’ lives!

Meet Delix Therapeutics at the 7th Annual Neuropsychiatric Drug Development Summit in Boston on September 24-26! Our CSO, Kurt Rasmussen, PhD and our CMO Aaron Koenig MD, will be speaking about Delix's groundbreaking advances of novel #neuroplastogens, #biomarkers, and #neuropsychiatry. Connect with our leadership team, including our CEO, Mark Rus, Head of Research and Development, Eliseo Salinas MD MSc, and Head of Corporate Strategy, Retsina Meyer, PhD, who will be available to discuss exciting, next-generation #innovations and future collaborations in the field.